Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 11, Issue 7 (2022)

Evaluation of fungicides against Pyricularia oryzae causing blast disease of rice

Author(s):
Nidhee Yadav, RS Netam, Prahlad Singh Netam and Nitesh Mehar
Abstract:
Rice blast caused by P. oryzae is an important disease posing a major threat to rice cultivation. Thus, we planned to conduct the evaluation of seven different fungicides against P. oryzae under in vitro and in vivo studies and were conducted. Among the in vivo studies of fungicides, the different concentrations at 500 ppm, 1000 ppm and 1500 ppm of Kitazin 48% EC found significantly effective against P. oryzae and its exhibited cent per cent inhibition of mycelial growth and % zone inhibition in all followed by Kasugamycin3% SL (2.53cm, 1.43 cm and 0.66 cm mycelia growth and 71.88%, 84.11% and 92.66% zone inhibition) at par with Tebuconazole 25.9% EC (3.76 cm, 2.53 cm and 1.00cm mycelial growth and 58.22%, 71.88% and 88.88% zone inhibition) and Thifluzamide 24% SC (4.0cm, 3.10 cm and 1.06cm mycelial growth and 55.55%, 65.55% and 88.22% zone inhibition). Similarly in in vitro study among different fungicides on the basis of two year pooled data, Kitazin 48% EC @ 1ml/liter water were found most effective for control of leaf blast severity (28.90%) and neck blast (23.12%) incidence followed by Kasugamyacin 3% SL @ 2.0 ml/ liter of water for leaf blast severity (31.66%) and neck blast incidence (24.65%), where the percent disease reduction over control was found effective in leaf blast 63.36% and neck blast 63.67%, followed by 59.86% and 61.27 respectively in Kasugamycin 3% SL. In percent increase yield over control were found significant in Kitazin 48% EC at 47.31% followed by Kasugamycin 3% SL at 45.77%.
Pages: 647-652  |  528 Views  343 Downloads


The Pharma Innovation Journal
How to cite this article:
Nidhee Yadav, RS Netam, Prahlad Singh Netam, Nitesh Mehar. Evaluation of fungicides against Pyricularia oryzae causing blast disease of rice. Pharma Innovation 2022;11(7):647-652.

Call for book chapter